Company Filing History:
4 out of 8 
2 out of 444 
Years Active: 2021-2025
Title: Florian A. Lempp: Innovator in Coronavirus Research
Introduction
Florian A. Lempp is a prominent inventor based in San Francisco, CA, known for his significant contributions to the field of biotechnology. With a total of four patents to his name, Lempp has focused his research on developing innovative solutions to combat viral infections, particularly those associated with coronaviruses.
Latest Patents
Among his latest patents, Lempp has developed "Coronavirus IRNA compositions and methods of use thereof." This invention relates to RNA interference (RNAi) agents, specifically double-stranded RNA agents that target the coronavirus genome. The patent outlines methods for using these RNAi agents to inhibit the expression of the coronavirus genome and to treat or prevent diseases associated with the virus. Another notable patent is for "Antibodies against SARS-CoV-2 and methods of using the same." This disclosure provides antibodies and antigen-binding fragments that can bind to a SARS-CoV-2 antigen, with capabilities to neutralize SARS-CoV-2 infections. It also includes polynucleotides encoding these antibodies, along with vectors and host cells that comprise these polynucleotides, pharmaceutical compositions, and methods for their use in treating or diagnosing SARS-CoV-2 infections.
Career Highlights
Florian A. Lempp has worked with leading biotechnology companies, including Vir Biotechnology, Inc. and Alnylam Pharmaceuticals, Inc. His work in these organizations has been pivotal in advancing research and development in the field of viral therapeutics.
Collaborations
Throughout his career, Lempp has collaborated with notable professionals in the industry, including Davide Corti and Katja Fink. These collaborations have contributed to the success of his research and the development of innovative solutions in biotechnology.
Conclusion
Florian A. Lempp stands out as a key inventor in the fight against viral infections, particularly in the context of coronaviruses. His patents and collaborations reflect his commitment to advancing medical science and improving public health outcomes.